Pre Clinical Studies on Gutgard

Pre-clinical studies on GutGard^®

Preclinical In vivo study

Anti-ulcer effect of GutGard^® was studied in various gastric ulcer models like pylorus ligation-, cold-restraint stress- and indomethacin induced gastric mucosal injury in Albino Wistar rats. Anti-ulcer activity was evaluated by measuring the ulcer index, gastric content, total acidity, and pH of gastric fluid. GutGard^® dose dependently decreased gastric content (p?0.05), total acidity, ulcer index (p?0.05) and increased pH of gastric fluid in pylorus ligation ulcer model. In cold-restraint stress- and indomethacin induced ulcer models all the doses of GutGard^®decreased the ulcer index (p?0.05) and increased the pH of gastric fluid.

Preclinical In vitro study

Inhibition of LPS induced release of NO, IL-1 β and IL-6.

Pro-inflammatory cytokines are the cytokines that promotes systemic inflammation. Inflammation is a beneficial host response to a foreign challenge or tissue injury that ultimately leads to the restoration of normal tissue structure and function. Prolonged inflammation contributes to the pathogenesis of many inflammatory diseases. The main pro-inflammatory mediators include cytokines, primarily TNF- α, IL-1, and IL-6. We have studied the effect of GutGard^® on the release of IL-1 β, IL-6 and NO in LPS-induced murine macrophages.|